linjc16/ctgov huggingface dataset:
Serum-Ascites Albumin Gradient Analysis in Cancer Patients in Palliative Care

Study Overview
=================
Brief Summary
-----------------
Current recommendations do not recommend the concomitant administration of albumin after ascites puncture in patients with ascites neoplasia unlike cirrhotic ascites. The etiology of ascites in cancer patients is multifactorial, particularly by hepatic invasion that can lead to ascites loaded with albumin. Ascites punctures therefore lead to undernutrition, recurrent early ascites by decreasing the oncotic pressure by hypo albuminemia and a state of anasarca affecting the quality of life.

Detailed Description
-----------------
According to the recommendations, each ascites fluid must be sent for biochemical and bacteriological analysis. Demonstrate the high gradient proportion (percent only, no threshold of significance required). The literature has already validated the importance of supplementing albumen with cirrhotic ascites. Demonstrating that some cancer patients have high gradients, this will be enough to make the practitioner think to supplement.

Official Title
-----------------
Serum-Ascites Albumin Gradient Analysis in Cancer Patients in Palliative Care

Conditions
-----------------
Solid Cancer in a Palliative Situation With Ascites

Intervention / Treatment
-----------------
* Diagnostic Test: cirrhotic albumin
* Diagnostic Test: serum albumin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient over 18 years of age followed for a solid cancer in a palliative metastatic situation who had a puncture of ascites. Exclusion Criteria: Minor patient Known cirrhosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| solid cancer in a palliative situation with ascites<br>Patient over the age of 18, followed for a solid cancer in a palliative metastatic situation, having had a puncture of ascites. | Diagnostic Test: cirrhotic albumin<br>* Ascites puncture<br>Diagnostic Test: serum albumin<br>* blood punctures<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum-Ascites Albumin Gradient Prevalence | Elevated Serum-Ascites Albumin Gradient Prevalence in Palliative Cancer Patients | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metastatic sites | Number of Metastatic sites of patients with a high gradient. | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
palliative, solid tumor, ascites
Pelvic and Acetabular Fracture in Old People

Study Overview
=================
Brief Summary
-----------------
It was reported that satisfactory postoperative outcome was difficult to obtain for the pelvic or acetabular fracture in old people. The less invasive surgical method was conducted in this study. Then, the clinical results were compared with the patients treated using traditional methods to assess the less invasive method.

Detailed Description
-----------------
Pelvic or acetabular fractures were caused by high energy trauma, which may lead to poor prognosis for the old. The patients over 60 years were included in this study. The surgical procedure was conducted in two weeks. The less invasive methods involved Stoppa approach and novel plate. The data including surgical time, blood loss and results of follow-up were recorded. The clinical results were compared with the patients treated using traditional methods. Thus, the clinical outcome of Pelvic or acetabular fractures in old man was assessed.

Official Title
-----------------
Different Surgical Methods for Pelvic or Acetabular Fracture of Old Man

Conditions
-----------------
Fracture Dislocation

Intervention / Treatment
-----------------
* Procedure: less invasive method


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 60 years old Fracture involving pelvis or acetabulum Operation was conducted within 14 days Sign the consent form Exclusion Criteria: Presented with a pathologic acetabular fracture Refused to participate Follow-up insufficient 12 months

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: clinical outcome<br>Less invasive method was applied to pelvic or acetabular fracture of old people. Thus, the clinical outcome of Pelvic or acetabular fractures in old man was assessed. | Procedure: less invasive method<br>* The less invasive surgical method was conducted in this study. Then, the clinical results were compared with the patients treated using traditional methods to assess the less invasive method.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fracture union time | how long the fracture line disappeared postoperatively in radiograph | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complication | wound infection, iatrogenic injury of vessels and nerves, nonunion | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fracture, outcome, pelvic, acetabular
Sedation Regimen in Patients Undergoing Cardiac Electrophysiology Study and Ablation : a Comparison Between Dexmedetomidine-remifentanil and Midazolam-remifentanil Combinations

Study Overview
=================
Brief Summary
-----------------
Cardiac ablation is an invasive procedure requiring anesthetic support for immobility and analgesia. Benzodiazepines and opioids are the most commonly used agents, while they are associated with respiratory depression and hypotension. The aim of this study was to compare the effect of remifentanil and dexmedetomidine, which exerts sedative and analgesic effect without serious respiratory depression, with conventional midazolam/remifentanil combination on sedative and analgesic levels in patients undergoing endocardial ablation.

Conditions
-----------------
Cardiac Arrhythmia

Intervention / Treatment
-----------------
* Drug: dexmedetomidine-remifentanil
* Drug: midazolam-remifentanil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients scheduled for elective cardiac ablation for atrial fibrillation Exclusion Criteria: ASA physical status class ≥ 3, respiratory disease, end stage renal disease, illiterate

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: dexmedetomidine-remifentanil<br>intravenous infusion of 0.2-0.7 µg/kg/h of dexmedetomidine after a loading dose of 1 µg/kg over 10 min | Drug: dexmedetomidine-remifentanil<br> <br> |
| Active Comparator: midazolam-remifentanil<br>remifentanil 3.6-7.2 mcg/kg/h midazolam 1-2mg | Drug: midazolam-remifentanil<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of sedation depth | Ramsay sedation score (1 = anxious and agitated, restless; 2 = cooperative, oriented, tranquil; 3 = responsive to verbal commands, drowsy; 4 = asleep, responsive to light stimulation; 5 = asleep, slow response to stimulation; 6 = no response to stimulation) the bispectral index | 5 min after study drug adminstration, and every 10 min thereafter | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiac ablation
Retrospective Study to Evaluate the Feasibility of Ovarian Preservation in Patients With Endometrial Carcinoma

Study Overview
=================
Brief Summary
-----------------
Endometrial cancer is one of the most common female malignancies in the United States, and has increased in incidence in Taiwan in recent decades.A recent population-based analysis noted that 4% of endometrial cancers occurred in women aged 40 years or younger, furthermore it is up to 15% in Taiwan according to the data of cancer registry. The standard treatment of endometrial cancer results in surgical menopause and places patients at risk for the long-term sequelae of estrogen deprivation. The goal of this study was to determine the frequency of a coexisting ovarian malignancy and to evaluate the outcome of ovarian preservation in women with treatment for endometrial cancer.

Detailed Description
-----------------
we reviewed the cases with early stage of endometrial cancer who have primary staging surgery between January 1989 to December 2009. The enrolled patients will be divided into two group (oophorectomy vs. ovary preservation) for analysis:the outcome and recurrence type.To evaluate the outcome of ovarian preservation in women with endometrial cancer .

Official Title
-----------------
Study for Elevate the Feasibility of Ovarian Preservation With Endometrial Carcinoma

Conditions
-----------------
Endometrial Cancer

Intervention / Treatment
-----------------
* Procedure: surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: early stage endometrial cancer after primary surgery exclusion criteria: MMMT, type 2 endometrial cancer

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ovarian preservation<br>endometrial cancer with ovarian preservation | Procedure: surgery<br>* endometrial cancer with or without oophorectomy<br>* Other names: staging surgery with ovarian preservation;|
| oophorectomy<br>endometrial cancer without ovarian preservation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| from the time of diagnosis to the time of disease recurrence or last follow time | the time of diagnosis to the time of disease recurrence or last follow time | disease recurrence or last follow time, up to one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ovarian preservation
Diagnostic Accuracy of Bedside Ultrasonography in the Management of the Shoulder Dislocations

Study Overview
=================
Brief Summary
-----------------
Shoulder dislocation is a common clinical presentation in the emergency department, comprising about 50 percent of all major joint dislocations. In the standart management of shoulder dislocations physicians generally need to see pre and post reduction x ray graphics. Ultrasonography is harmless way of evaluating shoulder and may be used in the management of the shoulder dislocations instead of the x ray evaluations.

Detailed Description
-----------------
Shoulder dislocation is a common clinical presentation in the emergency department, comprising about 50 percent of all major joint dislocations. In the standard management of shoulder dislocations physicians generally need to see pre and post reduction x ray graphics. Ultrasonography is harmless way of evaluating shoulder and may be used in the management of the shoulder dislocations instead of the x ray evaluations.Recent literature has demonstrated the superiority of point-of-care ultrasonography (POCUS) in detecting both anterior and posterior shoulder dislocations, making it another rapidly evolving tool to improve accuracy, decrease error, and improve efficiency. The aim of the study is to evaluate the accuracy and clinical usability of ultrasonography in the management of the shoulder dislocations.

Official Title
-----------------
Diagnostic Accuracy of Bedside Point of Care Ulrasound (POCUS) in the Management of the Shoulder Dislocations

Conditions
-----------------
Shoulder Dislocation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients over 14 years with suspected shoulder dislocation Accept to be participating Exclusion Criteria: Patients under 15 years of age Diagnosed before pocus evaluation Open fracture dislocations of the shoulder

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic accuracy of emergency physician performed point of care ultrasonography of shoulder in diagnosing of shoulder dislocations |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pocus, ultrasonography, glenohumeral dislocation
Study Evaluating Rhapsody Registry in Patients With Depression and Anxiety

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the prevalence of Major Depression and/or Anxiety Disorder in patients consulting the General Practitioner with acute or chronic painful physical symptoms and to identify risk factors.

Official Title
-----------------
An Observational Study on the Presence of Depression and/or Anxiety Disorder in Patients Consulting the General Practitioner With Painful Physical Symptoms in Belgium and Luxemburg.

Conditions
-----------------
Pain, Depression, Anxiety Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Outpatient must be at least 18 years of age Consulting a General Practitioner for painful physical symptoms Written informed consent Exclusion Criteria: Patient is unable to understand and comply with procedures of the study Patient is unable to complete the patient ratings Patient has an acute pain with an obvious cause

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain, depression, anxiety disorder
Quality of Life After Laparoscopic Removal of Essure®

Study Overview
=================
Brief Summary
-----------------
A lot of patients seem to complain after hysteroscopic tubal occlusion by Essure® device with a worce quality of life. Investigators' hypothesis is that Essure® laparoscopic removal may improve quality of life. This prospectice study aim to assess the quality of life 1, 3, 6 and 12 months after Essure® removal.

Official Title
-----------------
Prospective Study of Quality of Life After Laparoscopic Removal of Essure®

Conditions
-----------------
Contraceptive Device; Complications, Quality of Life

Intervention / Treatment
-----------------
* Other: Quality of life after Essure® removal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women aged 18 years or more patients with Essure® sterilization device surgical removal of Essure® with bilateral salpingectomy by laparoscopy Exclusion Criteria: interview revealing disorder entailing unacceptable risk of postoperative complications: coagulation disorder, immune system disorder, evolutive disease, etc. impaired lower-limb range of motion preventing positioning for surgery inability to understand information provided prisoner or under administrative supervision.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Essure®<br>Patients with laparoscopic removal of Essure® | Other: Quality of life after Essure® removal<br>* Questionnaire to assess the quality of life 1, 3, 6 and 12 months after laparoscopic removal of Essure® device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life 1 month after laparoscopic removal of Essure® | Questionnaire to assess the quality of life 1 month after laparoscopic removal of Essure® device | 1 month |
Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone

Study Overview
=================
Brief Summary
-----------------
This study is conducted in Europe. The purpose of this study is to assess the impact on daily life for children new to using a growth hormone injection device.

Official Title
-----------------
Ease of Use and Tolerability of Norditropin NordiFlex® in Growth Hormone naïve Children: Impact on Daily Life

Conditions
-----------------
Growth Hormone Disorder, Growth Hormone Deficiency in Children, Genetic Disorder, Turner Syndrome, Foetal Growth Problem, Small for Gestational Age, Chronic Kidney Disease, Chronic Renal Insufficiency, Delivery Systems

Intervention / Treatment
-----------------
* Drug: Norditropin NordiFlex®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Growth hormone (GH) treatment naïve subjects for whom it has been decided to initiate GH treatment prior to enrollment into the study Subjects who receive Norditropin NordiFlex® according to the SPC Exclusion Criteria: Known or suspected allergy to study product(s) or related products Child and/or parent unable to give consent or fill out the questionnaires The receipt of any investigational medicinal product within 3 months prior to this study Suffer from a life-threatening disease

Ages Eligible for Study
-----------------
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Norditropin NordiFlex® users<br> | Drug: Norditropin NordiFlex®<br>* Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Usability of growth hormone injection device assessed by a quantitative scale |  | after 3 months of growth hormone treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of adverse events |  | from 0 - 3 months of growth hormone treatment | 
| Number of technical complaints |  | from 0 to 3 months of growth hormone treatment |
Neuromarker S-100B as Diagnostic Tool

Study Overview
=================
Brief Summary
-----------------
The hypothesis of this study is to find evidence if there is an influence of spine surgery on the serum levels of two proteins secreted from neuronal cells.

Detailed Description
-----------------
The question, if there is an effect on the cerebrospinal system during spine surgery, which can be traced by monitoring serum levels of neuromarkers is not yet answered. This study has its background from other studies on patients with traumatic brain injury (TBI), in whom elevated serum levels of the two neuromarkers S-100B and NSE are associated with injury severity, neuronal damage, brain, tissue damage, and outcome. Patients undergoing spine surgery with or without pre-existing traumatic neurologic symptoms are planned to be the study cohort. Pre- and postoperatively the serum levels of S-100B and NSE are obtained and are statistically compared with patients undergoing other types of bone-related surgery.

Official Title
-----------------
Elevated Levels of S-100B and Neuron-specific Enolase (NSE) in Spine Surgery: A Comparison of Serum Levels With Surgery for Long-bone Fractures

Conditions
-----------------
Spinal Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: spine fracture Exclusion Criteria: additional traumatic brain injury fractures of the long bones polytrauma severely injured patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Spine surgery<br>Patients undergoing spine surgery | |
| Bone surgery<br>Patients undergoing bone surgery for fracture treatment other than spine fractures | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| S-100B levels | average timeframe between blood withdrawal (twice, pre-and post-operatively) | 4 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NSE, S-100B